Agenda for Day 2 - Tuesday 10 November, 2026
Location: Clinical Strategy Stage
Have you ever wondered what the future holds for clinical operations? More importantly, how can we prepare for what lies ahead? This session gives the audience a glimpse into the future by exploring the challenges to come and recommending solutions to implement now, in preparation for tomorrow.
Explore how AI and global expansion are reshaping clinical trials, unlocking innovation and transforming operational efficiency across international markets
Discuss the role of community engagement in driving operational excellence, fostering trust and improving patient participation and retention
Identify disruptive pathways to accelerate trial timelines and navigate the evolving landscape of decentralised trials, patient diversity and digitalization
- Bernhard Glombitza - Head of Clinical Operations & Customer Engagement EMEA / LATAM, Bayer AG
Location: Clinical Strategy Stage
Identify evidence gaps that could affect European development and market access, and the questions Western buyers should resolve with clinical, regulatory and HTA specialists before committing.
Assess whether China-origin clinical data meets European regulatory standards, identify critical evidence gaps, and determine what bridging studies or additional trials are required to support your regulatory and market-access strategy
Understand how data ownership rights, ongoing reliance on China-based CROs or trial sites, and regulatory responsibilities impact your clinical development timeline, budget, and operational control post-transaction
Determine when geopolitical factors—including export controls, supply chain constraints, and regulatory scrutiny of China-origin assets—require you to revise your development plan, restructure the deal, or walk away from the transaction entirely
- Chenchao Liu - Founder & Managing Director, SILREAL GmbH
Location: Clinical Strategy Stage
Examine what Western partners must resolve on evidence, data access and policy risk before committing to a China-origin asset
Understand how to leverage China’s speed, patient access and regulatory flexibility to accelerate global development timelines
Explore the surge in licensing agreements between global pharma and Chinese innovators and what makes China attractive for global partnerships
Understand the regulatory evolution in the regional and their impact on development
- Chenchao Liu - Founder & Managing Director, SILREAL GmbH
- Stella Gu - General Manager, Tigermed Swiss AG
- Echo Hindle-Yang - Founder & CEO, MSQ Ventures
- Seemi Khan - Chief Development & Strategy Officer, Alkeus Pharmaceuticals
Location: Clinical Strategy Stage
Examine cost-benefit frameworks for bridging studies across Japan, Korea, Taiwan and ASEAN countries, balancing regulatory requirements, ethnic sensitivity considerations and commercial ROI to accelerate regional approvals
Explore the unique regulatory pathways and requirements across key Asian markets, including PMDA (Japan), MFDS (Korea), TFDA (Taiwan) and emerging frameworks in Southeast Asian nations
Discuss proven strategies for managing multi-country trials in the region, including site selection and engagement in mature and emerging markets, patient recruitment in heterogeneous populations and building sustainable partnerships with local CROs and research institutions
Future-Proof emerging opportunities across Southeast Asia's growing clinical trial ecosystem, the rise of decentralized and hybrid trial models adapted to Asian healthcare systems and how to leverage real-world evidence and digital health innovations tailored to local market needs
- Barbara Kienast - Head of Clinical Operations & Regulatory Affairs, Graythan Regulatory Services
- Christina Chang - Global CMO, HiRO
- Shin Nagase - Senior Director, Deputy Head of Asia CRO Business, CRO & Consulting UNIT, CMIC Group
- Catherine Sherwin - Chief Regulatory and Clinical Pharmacology Officer, Differentia Bio
Location: Clinical Strategy Stage
Address unique regulatory hurdles and innovative approval pathways for rare disease clinical trials, including adaptive designs and strategies for generating robust evidence with limited patient populations
Examine the impact of political and leadership changes at the FDA and across global regulatory agencies, and how these shifts influence drug development priorities, review timelines, and enforcement approaches
Align trial design with evolving regulatory requirements by incorporating real-world evidence, digital endpoints, and quality-by-design principles that strengthen submissions and accelerate approvals
- Sinan Sarac - Senior VP, Head of Regulatory Science - Oncology, Parexel
- Zoltan Magyarics - VP, Research & Development, AOP Health
Location: Clinical Strategy Stage
Australia offers a compelling opportunity for clinical trials, with favorable regulatory framework, strong networks, excellent engagement with clinicians/researchers, and access to established and proven pathways of obtaining high-quality clinical data recognised by European and US regulators, and other global institutions. This speaking session will highlight how Australia’s clinical trials are a cornerstone for innovation and attractive environment for companies from around the world to develop their intellectual property.
- Chris Stellatos - Corporate and Business Development, Scientia Clinical Research Ltd
- Matthew Bugg - COO, MaH Pharma Pty Ltd
- Morgan Evans - CSO, Agilex Biolabs
- Teresa Karnatz - Senior Director of Business Development (Europe & UK), Biocina Pty Ltd
- Meredith Manuel - Head of Business Development, Avion CRO & Imaging Specialists
Location: Clinical Strategy Stage
Learn best practices for strategic trial hub positioning globally, CRO selection, and building local partnerships to accelerate trial timelines while navigating the balance between market access and recruitment feasibility
Address infrastructure and resource challenges in emerging markets by understanding the patient journey, establishing strong site relationships, and implementing effective strategies for working in diverse regions
Discover actionable approaches for expanding trial footprints into underserved populations, including conducting proper due diligence and research to identify optimal locations for clinical trial success
- Maya Zlatanova - CEO, TrialHub
Location: Clinical Strategy Stage
As Europe positions itself as a leading destination for clinical research, the ability to deliver clinical trials at scale requires robust operational frameworks and strategic site management. This fireside chat explores what it takes to transform Europe into a thriving clinical trials hub, examining the critical operational elements that enable successful trial execution across diverse European markets.
Assess the regulatory, infrastructure, and market factors positioning Europe as an attractive hub for clinical research
Learn how to evaluate site capabilities and optimize performance using data-driven approaches tailored to Europe's diverse healthcare systems
Understand best practices for streamlining study initiation processes, managing cross-border logistics, and accelerating timelines
- Pilar de la Rocha Mur - VP, Head of EMEA, Global Clinical Operations, BeOne Medicines
- Paul Miller - CCO, Optimapharm
Location: Clinical Strategy Stage
Discover how AI streamlines clinical trial operations- from intelligent protocol development and patient recruitment to digital twin technology that reduces patient requirements while maintaining regulatory compliance
Learn strategies for shifting from traditional site-centric approaches to patient-focused trial designs that improve accessibility, diversity, and retention through decentralized and hybrid methodologies
Explore real-world case studies and expert predictions on AI's future impact in precision medicine, regulatory evolution, and the transformation of clinical research operations
- Murali Nair - Director, Business Development, PharmSky Research
- Sougato Das - Senior Director, Product Management, TransPerfect
- Paul Little - CEO, Atrogi
- Jane Twitchen - Executive Director, Head Clinical Trial Accelerator Unit, Biogen
